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We investigated the eﬀect of LPS in vitro stimulation on T-cell activation in HIV-infected patients with diﬀerent CD4+ recovery
on HAART. PBMCs from 30 HIV-positive, HAART-treated, aviremic individuals with diﬀerent CD4+ reconstitution (Low
Responders: CD4+ < 350/µL; Intermediate Responders: CD4+ 350–599/µL; High Responders: CD4+ ≥ 600/µL) were cultured
with LPS and the proportion of HLA-DR/CD38- and Ki67-expressing CD4+/CD8+ T-cells was measured (flow cytometry). Upon
LPS stimulation, significantly higher CD4+ and CD8+HLA-DR+ cells were shown in LR and IR versus HIV-negative controls.
While no diﬀerences in the proportion of LPS-stimulated CD4+CD38+ cells were recorded amongst HIV-positive subgroups,
CD8+CD38+ cells were more elevated in patients with lower CD4+ recovery on HAART (i.e., LR and IR). Upon in vitro LPS
stimulation, HLA-DR and CD38 expression on T-cells are diﬀerentially regulated. While HLA-DR induction reflects impaired
CD4+ reconstitution on HAART, cell-surface CD38 expression is increased only on CD8+ T-cells, allowing to speculate that the
sole induction of CD38 on CD4+ cells may not be suﬃcient to depict LPS-driven immune activation in HIV.
1. Introduction
Untreated HIV disease is characterized by high levels of T-
cell activation which account for the progressive depletion of
CD4+ T-cells [1, 2].
Microbial translocation, which occurs following the
breakdown of the gastrointestinal barrier, has been put
forward as a possible mechanism underlying immune acti-
vation in HIV disease [2, 3]. Most interestingly, microbial
translocation-induced T-cell hyperactivation may also repre-
sent a cause of impaired immune restoration on virologically
suppressive HAART [4–6], as suggested by high levels of
circulating lipopolysaccharide (LPS) in patients with poor
CD4+ T-cell recovery in course of eﬀective treatment [4].
In keeping with these observations, in vitro exposure
of PBMCs to LPS and other Toll-Like Receptor (TLR)
agonists has been shown to induce the expression of CD38,
indicator of T-cell activation, on CD4+ and CD8+ T-cells
in healthy individuals [7], thus suggesting a model for HIV
pathogenesis. Indeed, CD38 upregulation on CD8+ cells has
been consistently described in HIV infection and correlates
with disease progression better than HIV RNA load [8–
11]; conversely, the issue of whether high CD38 expression
on CD4+ T-cells is a marker of poor prognosis [8, 9, 11,
12] has been debated for some time [13]. Taken together,
these findings imply that the actual biological significance
of CD38 in the context of HIV/AIDS remains elusive,
given the multiple functions it retains [14]. Indeed, along
with its association with T-cell activation, recent data have
demonstrated that CD38 on CD4+ cells may also identify a
hypoproliferating cell subset, thus oﬀsetting the paradigm of
CD38 as T-cell activation marker [13, 15].
In the light of these premises, we investigated the
dynamics of HLA-DR and CD38 expression on peripheral T-
cells following selective in vitro LPS stimulation of PBMCs
from HIV-infected HAART-treated individuals. We hypoth-
esized that LPS may account for diverse levels of immune
activation in HIV-infected patients according to the degree
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of immunological recovery in course of suppressive HAART.
We also hypothesized that HLA-DR and CD38 may not
be equivalent in reflecting the extent of T-cell activation
following in vitro stimulation with LPS in the setting of HIV
disease.
2. Materials and Methods
2.1. Patients. HIV-positive, HAART-treated patients for
at least 12 months, with undetectable HIV RNA load
(<40 cp/mL) and a CD4+ T-cell nadir <250/µL, were consec-
utively enrolled at the Clinic of Infectious Diseases and Trop-
ical Medicine, “San Paolo” Hospital, University of Milan,
Italy. Patients were divided into 3 groups according to the
degree of immune-reconstitution in course of HAART: high
responders (HRs) with CD4+ ≥600/µL, and low responders
(LRs) with CD4+ <350/µL; intermediate responders (IR)
with CD4+ 350–599/µL. As controls, HIV-negative age-
matched subjects were studied. Written informed consent
forms approved by the Ethical Committee of the “San Paolo”
Hospital, University of Milan, Italy, were obtained from all
participants.
2.2. Laboratory Methods
2.2.1. Plasma HIV RNA Levels. Plasma HIV-1 RNA levels
were quantified by means of a nucleic acid signal amplifica-
tion assay (Abbott Real-Time PCR assay), which has a lower
detection limit of 40 HIV RNA copies/mL of plasma.
2.2.2. Lymphocyte Immunophenotype Analysis. Fresh periph-
eral blood was drawn from all study participants in EDTA-
containing tubes and PBMCs were separated by Ficoll-
Histopaque technique (Biocoll separating solution, BIOSPA)
(T0). Cells were counted and 5×106 cells were cultured in
R10 medium alone (composition per 100mL R10: 88mL
RPMI, 10mL fetal bovine serum, 1mL [100UI/mL] L-
glutamine, and 1mL [100UI/mL] penicillin/streptomycin;
Euroclone, Italy) (unstimulated, US) or in medium supple-
mented with LPS for 24 hours (T1) and 48 hours (T2) (E.
coli; 026 : B6∗C, Sigma-Aldrich,Milan, Italy, 20 ng/mL; stim-
ulated, STIM). Prior to and following stimulation, cells were
recounted and stained (CD4+/CD8-PerCP Cy5.5, HLA-DR-
FITC, CD38-PE; Ki67-FITC, Becton Dickinson, San Jose`,
CA, USA) for flow cytometric analysis of HLA-DR, CD38,
and Ki67 expression on T-cells (Cytomics FC500, Beckman
Coulter, Hialeah, FL, USA) using CXP 2.2. software.
2.3. Statistics. Data were analyzed with GraphPad 5
PRISM software. Mann-WhitneyU-test, Kruskall-Wallis and
Wilcoxon tests were used for statistics. All statistical tests
were 2-sided and diﬀerences were considered statistically
significant at P < 0.05.
3. Results
3.1. Patients. 30 HIV-positive, HAART-treated patients with
undetectable HIV RNA load were enrolled. According to the
degree of immune-reconstitution onHAART, 9 HIV-positive
patients were HR (CD4+ ≥600/µL), 9 resulted LR (CD4+
<350/µL), and 12 intermediate IR CD4+ 350–599/µL. 15
HIV-negative age-matched subjects were also studied.
Duration of HIV infection was comparable in all subjects
(LR: 7 months, IQR 5–19; IR: 13 months, IQR 8–22; HR: 12
months, IQR 6–23; P > 0.05 for all comparisons; Table 1).
All patients were on HAART for at least 12 months prior to
evaluation, with no diﬀerences in terms of HAART duration
(LR: 71 months, IQR 46–141; IR: 106 months, IQR 65–149;
HR 71 months, IQR 39–132; P > 0.05 for all comparisons;
Table 1) and drug regimen (Table 1).
HRs were significantly younger compared to LRs (HR:
39 years, IQR 35–44; LR: 50 years, IQR 45–56; P = 0.02;
Table 1) and presented higher absolute CD4+T-cell counts as
defined by inclusion criteria (LR: 260/µL, IQR 215–339; IR:
498/µL, IQR 425–537; HR: 726/µL, IQR 608–863; P < 0.01
for all comparisons; Table 1). A trend to lower CD4+ T-
cell nadir was found in patients with less eﬃcient immune-
reconstitution, (LR: 90/µL, IQR 51–179; IR: 105/µL, IQR 45–
208; HR: 204/µL, IQR 56–240; P > 0.05 for all comparisons)
reaching statistical significance for percentage values in LR
versus HR (LR: 8%, IQR 5–17; HR: 26%, IQR 22–30; P =
0.03; Table 1).
No other significant diﬀerences in demographic and
HIV-related parameters were observed among groups
(Table 1).
3.2. Lymphocyte Immunophenotype Analysis
3.2.1. HLA-DR Expression on CD4+ and CD8+ T-Cells upon
LPS Stimulation. At T0, HIV-positive patients displayed a
tendency to higher HLA-DR+CD4+/CD8+ compared to
controls, reaching significance for the CD4+ T-cell subpop-
ulation (CD4+: 30%, IQR 20–54 versus 19%, IQR 5–28; P =
0.02; Figure 1(a); CD8+: 32%, IQR 18–50 versus 21% IQR
11–39; P = 0.07; Figure 1(c)), with no diﬀerences according
to immune-reconstitution (Figures 1(b), and 1(d)).
At T1, following LPS stimulation, HIV-infected individ-
uals as a whole displayed a non-significant trend to increased
HLA-DR+CD4+ (19%, IQR 14–33 versus 13%, IQR 11–
26; P = 0.08; Figure 1(e)) and HLA-DR+CD8+ (23%,
IQR 17–37 versus 18%, IQR 13–29 P = 0.2; Figure 1(g))
when compared to healthy controls. Interestingly, when
analysing patients according to CD4+ recovery on HAART,
LPS stimulation resulted in significant upregulation of HLA-
DR on CD4+ T-cells in LR (32%, IQR 19–50) compared
to HR (15%, IQR 11–21; P = 0.03; Figure 1(f)) and
controls (P = 0.03; Figure 1(f)). Conversely, no diﬀerences in
HLA-DR-expressing proportions upon LPS stimulation were
observed in the CD8+ compartment at this timepoint (LR:
28%, IQR 16–50; IR: 24%, IQR 18–50; HR: 18%, IQR 15–32;
P > 0.05 for all comparisons; Figure 1(h)).
At T2, HIV-positive subjects displayed significantly
higher LPS-induced HLA-DR+CD4+ (24%, IQR 14–44.3
versus 12%, IQR 8–23; P = 0.006; (i)) and HLA-DR+CD8+
cells (26%, IQR 18–34 versus 13%, IQR 7–25; P =
0.005; (k)). Following stimulation with LPS, a CD4+ T-
cell activation hierarchy was maintained in LR (32%, IQR
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Table 1: Demographic characteristics and viro-immunological parameters of the patients in study.
Characteristic
LR
(n = 9)
IR
(n = 12)
HR
(n = 9)
Age, years (IQR) 50 (45–56) 48 (38–60) 39 (35–44)a
Sex, F (%) 2 (22) 3 (25) 3 (33)
Risk factors for HIV infection
MSM, n (%)
heterosexual, n (%)
IDU, n (%)
2 (22)
6 (67)
1 (11)
5 (42)
4 (33)
3 (25)
1 (11)
3 (33)
5 (56)
Duration of HIV infection, years (IQR) 7 (5–19) 13 (8–22) 12 (6–23)
HAART duration, months (IQR) 71 (46–141) 106 (65–149) 71 (39–132)
Diagnosis of AIDS, n 4 3 2
Absolute T CD4+ cell counts, cell/µL (IQR)
at the time of study
nadir
260 (215–339)
90 (51–179)
498 (425–537)
105 (45–208)
726 (608–863)a
204 (56–240)
Percentage T CD4+ cell counts, % (IQR)
at the time of study
nadir
26 (16–34)
8 (5–17)
27 (22–33)
18 (13–22)
31 (25–43)
26 (22–30)
Plasma HIV RNA, log10cp/mL (IQR)
zenith
at the time of study
5.3 (4.5–5.9)
1.7
5.4 (4.1–5.7)
1.7
4.4 (3.9–5.2)
1.7
HAART regimen
Number of patients at the time of study
NRTI+PI
NRTI+NNRTI
Other
5
2
2
7
4
1
4
3
2
Data are presented as median and interquartile range (IQR). LR: Low Responders (CD4+ < 350/µL, HIV RNA < 40 cp/mL); IR: Intermediate Responders
(CD4+ 350–599/µL, HIV RNA < 40 cp/mL); HR: High Responders (CD4+ ≥ 600/µL, HIV RNA < 40 cp/mL); MSM: Men having sex with men; IDU:
Intravenous Drug Users; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: nonnucleoside reverse-
transcriptase inhibitor; PI: protease inhibitor. aP < 0.05 for diﬀerences among groups.
15–40) and IR (28%, 14–48) over HR (21%, IQR 13–37;
P = 0.4; P = 0.5, resp.; (j)), reaching statistical significance
in comparison with HIV-negative controls (P = 0.02 and
P = 0.03, resp.; (j)). Similar results were observed in terms
of LPS-induced expression of HLA-DR on CD8+ cells, with
increased levels in LR (28%, IQR 22–45) and IR (28%, IQR
15–33; (l)) compared to controls (P = 0.007 and P = 0.05)
(l).
A graphical time-course representation of the eﬀect of
LPS stimulation on HLA-DR in HIV-infected individuals
with diﬀerent response to HAART and in HIV-negative
controls is summarized in Figure 3.
3.2.2. CD38 Expression on CD4+ and CD8+ T-Cells upon LPS
Stimulation. Baseline (T0) CD38+CD4+ cells were com-
parable in HIV-positive and HIV-negative patients (66%,
IQR 58–80 versus 66%, IQR 54–75, P = 0.4; Figure 2(a)).
Conversely, CD38+CD8+ cells were higher in HIV-positive
patients (55%, IQR 38–71 versus 38%, IQR 30–59, P = 0.05;
Figure 2(c)). In both cases, no diﬀerences amongst HIV-
infected subgroups were detected (Figures 2(b), and 2(d)).
Most interestingly, cells fromHIV-infected patients failed
to respond to LPS stimulation at T1, displaying significantly
lower proportions of CD38+CD4+ (64%, IQR 55–72.7
versus 73%, IQR 70–82; P = 0.02; Figure 2(e)) and
CD38+CD8+ (54%, IQR 39–67 versus 65%, IQR 55–70,
P = 0.05; Figure 2(g)) compared to HIV-negative controls.
However, within HIV-infected subjects, LR and IR showed
higher CD38+CD8+ (65%, IQR 48–70 and 56%, IQR 45–
71, resp.) compared to HR upon LPS stimulation (41%,
IQR 25–55; P = 0.04 for both comparisons; Figure 2(h)),
while CD38+CD4+ cells did not vary according to immune-
reconstitution (LR: 64%, IQR 55–78; IR: 62%, IQR 55–
75; HR: 64%, IQR 51–67; P > 0.05 for all comparisons;
Figure 2(f)).
At T2, HIV-positive and healthy individuals displayed
comparable CD38+CD4+ and CD8+ following LPS stimu-
lation (74%, IQR 65–80 versus 66%, IQR 61–77; P = 0.3;
Figure 2(i); 64%, IQR 50–70 versus 52%, IQR 42–63; P =
0.2; Figure 2(k)). similar to T1 data, LR presented higher
CD38+CD8+ than HR (66%, IQR 64–74 versus 49%, IQR
30–64, P = 0.01 Figure 2(l)) and controls (P = 0.02;
Figure 2(l)), whereas no diﬀerences in CD38+CD4+ cells
were noted amongst HIV-positive subgroups (LR: 74%, IQR
68–78; IR: 79%, IQR 71–83; HR: 60%, IQR 50–77; P > 0.05
for all comparisons; Figure 2(j)).
A graphical time-course representation of the eﬀect of
LPS stimulation on CD38 in HIV-infected individuals with
diﬀerent response to HAART and in HIV-negative controls
is summarized in Figure 3.
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Figure 1: HLA-DR-expressing CD4+/CD8+ T-cells in HIV-negative and HIV-positive patients prior to and following LPS stimulation.
HLA-DR expression was measured on freshly ficoll-separated CD4+ and CD8+ T-cells at baseline (T0, top), and following 24- (T1, middle)
and 48-hour (T2, bottom) LPS stimulation. PBMCs were cultured in medium alone (unstimulated, US) or in medium with 20 ng/mL LPS
(stimulated, STIM). At T0, HIV-positive individuals displayed higher HLA-DR+CD4+ (P = 0.02, (a)) and HLA-DR+CD8+ proportions
(c), with no diﬀerences amongst HIV-positive subgroups ((b) and (d)). At T1, HIV-positive patients maintained increased HLA-DR+CD4+
(e) and CD8+ cells (g); significantly higher HLA-DR+CD4+ levels were detected in LR versus HR and negative controls (P = 0.03 for both
comparisons, (f)). At T2, HIV-infected individuals displayed significantly higher HLA-DR+CD4+ (P = 0.006, (i)) and CD8+ cells compared
to controls (P = 0.005, (k)). Following stimulation, significantly greater proportions of HLA-DR-expressing CD4+ were measured in LR
(P = 0.02, (j)) and IR (P = 0.03, (j)) compared to controls. Comparable results were detected in the CD8+ compartment upon LPS
stimulation (LR versus HIV-negative, P = 0.007, (l); IR versus HIV-negative, P = 0.05, (l)). P values in the results section refer to stimulated
samples only.
3.2.3. HLA- DR/CD38 Co-expression on CD4+ and CD8+
T-Cells upon LPS Stimulation. At T0 comparable HLA-
DR+CD38+CD4+ cells were observed in HIV-negative
(15.4%, IQR 2.1–25.9) and HIV-positive patients (23.5%,
IQR 7.2–48.8; P = 0.08) with no diﬀerences among HIV
subgroups (LR: 20.2%, IQR 6.9–42; IR: 24.5%, IQR 8.1–63.1;
HR: 41.5%, IQR 12.1–49.5; P > 0.05 for all comparisons).
At T1, LPS did not account for significant changes in
HLA-DR/CD38 coexpression on CD4+ T-cells compared to
baseline values.
A completely diﬀerent scenario was pictured upon
LPS stimulation at T2, with significantly higher HLADR+
CD38+CD4+ in HIV-positive patients as a whole (20.3%,
IQR 12.1–39.4) and in LR subjects (LR: 20.3%, IQR 12.8–
34.4) compared to controls (9.5%, IQR 6.6–19.0; P = 0.04
and P = 0.03, resp.).
Similar results were observed in HLA-DR/CD38 coex-
pression on CD8+ T-cells, given that no diﬀerences among
study groups were detected at T0: HIV-negative: 13.6%, IQR
4.0–24.9; HIV-positive: 18.3%, IQR 12.1–42.2; LR: 17.9%
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Figure 2: CD38-expressing CD4+/CD8+ T-cells in HIV-negative and HIV-positive patients prior to and following LPS stimulation. CD38
expression wasmeasured on freshly ficoll-separated CD4+ and CD8+T-cells at baseline (T0, top) and following 24- (T1,middle) and 48-hour
(T2, bottom) LPS stimulation. PBMCs were cultured in medium alone (unstimulated, US) or in medium with 20 ng/mL LPS (stimulated,
STIM). At T0, comparable CD4+CD38+ were detected in HIV-positive patients and controls (a); however, the former displayed markedly
higher CD8+CD38+ (P = 0.05, (c)), with no diﬀerences amongst HIV-positive subgroups. At T1, a significantly lower expression of CD38
was detected on CD4+ (P = 0.02, (e)) and CD8+ cells (P = 0.05, (g)) from HIV-positive individuals despite LPS stimulation. While no
diﬀerences in CD4+CD38+ were recorded amongst HIV-positive subgroups (f), CD8+CD38+ cells were significantly higher in LR and IR
compared to HR (P = 0.04 for both comparisons, (h). At T2, LR presented highest CD38+CD8+ compared to HR (P = 0.01, (l)) and
controls (P = 0.02, (l)) with no diﬀerences in CD4+CD38+ (j). P values in the results section refer to stimulated samples only.
IQR 12.2–28.7; IR: 14.1%, IQR 8.0–45.7; HR: 30.5%, IQR
12.8–46.7 (P > 0.05 for all comparisons).
While LPS stimulation did not lead to significant dif-
ferences in terms of HLA-DR/CD38 induction on CD8+
cells at T1, significantly higher HLADR+CD38+CD8+ cells
were detected in HIV-positive patients compared to controls
(20.5%, IQR 10.5–29.0 versus 8.7%, IQR 4.9–20.1; P = 0.02)
at T2.
When examining patients with diﬀerent degree of im-
mune-reconstitution, LR maintained activation CD8+ acti-
vation hierarchy over HIV-negative individuals, with signif-
icantly more HLADR+CD38+CD8+ cells (LR: 24%, IQR
14.6–36.4; P = 0.02).
3.2.4. Ki67 Expression on CD4+ and CD8+ T-Cells upon LPS
Stimulation. At T0, no diﬀerences between HIV-negative
controls and HIV-positive subjects were measured in Ki67
expression on CD4+ (8.2%, IQR 4.0–17.2 versus 12.7%, IQR
2.6–18.2, res.; P = 0.7; Figure 4(a)) and CD8+ T-cells (1.9%,
IQR 0.1–3.7 versus 1.25; IQR 0.0–4.8; P = 0.8; Figure 4(c)).
T-cell proliferation levels did not vary according to the degree
of immune-reconstitution in course of HAART, despite trend
to higher Ki67 expression on CD4+ T-cells in HR (17%, IQR
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Figure 3: Time course representation of the eﬀect of LPS on HLA-DR and CD38 expression on CD4+ and CD8+ T-cells. Median HLA-DR
((a) and (b)) and CD38 ((c) and (d)) expression on CD4+ and CD8+ T-cells in HIV-positive and HIV-negative individuals (left portion of
graphs) and in HIV-infected subjects with diﬀerent immunological outcome in course of HAART (right portion of graphs) at baseline (T0)
and following LPS stimulation (T1 stim, T2 stim).
12.6–18.9) compared to LR (5.5%, IQR 1.4–15.5; P = 0.07;
Figure 4(b)).
At T1, LPS stimulation did not account for significant
increases in cell proliferation (Figures 4(e)–4(h)). Interest-
ingly, however at T2, a trend to increased Ki67 levels on
CD4+ T-cells upon stimulation was detected in LR (20.5%,
IQR 7.5–31.0) compared to HR (5.5%, IQR 2.0–12.6; P =
0.08) and negative controls (3.9%, IQR 0.4–18.7; P =
0.08; Figure 4(j)), thus mirroring the state of CD4+ T-cell
activation through the expression of HLA-DR (Figure 1(j)).
No diﬀerences were detected in terms of CD8+ T-
cell proliferation among study groups following 48-hour
stimulation with LPS (Figures 4(k), and 4(l)).
4. Discussion
We hereby investigated the induction of CD38, HLA-DR
and Ki67 on CD4+ and CD8+ T-cells following selective in
vitro LPS stimulation inHIV-infected individuals with diﬀer-
ent immunological recovery upon virologically suppressive
HAART.
We enrolled patients on stable antiretroviral therapy
and with comparable demographic and viro-immunological
parameters. Of note, patients with less eﬃcient immune-
reconstitution were significantly older and presented
decreased T CD4+ cell nadir compared to subjects displaying
sustained CD4+ T-cell recovery; this finding is in keeping
with literature data demonstrating that age and CD4+ cell
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Figure 4: Ki67-expressing CD4+/CD8+ T-cells in HIV-negative and HIV-positive patients prior to and following LPS stimulation. Ki67
expression wasmeasured on freshly ficoll-separated CD4+ and CD8+T-cells at baseline (T0, top) and following 24- (T1,middle) and 48-hour
(T2, bottom) LPS stimulation. PBMCs were cultured in medium alone (unstimulated, US) or in medium with 20 ng/mL LPS (stimulated,
STIM). At T0, no diﬀerences between HIV-negative controls and HIV-positive subjects were measured in Ki67 expression on CD4+ (a)
and CD8+ T-cells (c). T-cell proliferation levels did not vary according to the degree of immune-reconstitution in course of HAART ((b)
and(d)). At T1, LPS stimulation did not account for significant increases in cell proliferation ((e)–(h)). At T2, a trend to increased Ki67 levels
on CD4+ T-cells upon stimulation was detected in LR compared to HR and negative controls (j); no diﬀerences were detected in terms of
Ki67+CD8+ T-cells proliferation among study groups following 48-hour stimulation with LPS ((k) and (l)).
counts at HAART initiation are determinants of incomplete
immunological reconstitution in course of suppressive
HAART [16].
Our data show a diﬀerential eﬀect of LPS in vitro stimu-
lation on the cell-surface expression of two T-cell activation
markers, that is, HLA-DR and CD38: (i) despite an overall
reduction of HLA-DR+ T-cells, patients with an ineﬃcient
response to HAART display a higher proportion of activated
HLA-DR+CD4+/CD8+ compared to individuals with better
CD4+ recovery; (ii) CD38 expression is induced on T-cells,
and yet only the CD38+CD8+ pool is significantly expanded
according to the degree of immunological impairment.
HIV infection is characterized by high levels of immune
activation [1, 2] which is a major cause of the progressive
CD4+ T-cell loss in untreated disease [1, 2, 8–10] and
impaired immunological recovery in course of HAART
[5, 17]. A possible driver of immune activation is the
translocation of bacterial bioproducts, mainly LPS, through
the gastrointestinal barrier to the systemic circulation [2,
3]. Indeed, literature findings show that non-progressive
disease in SIV natural host primates associates with no
microbial translocation and/or immune activation [18, 19];
conversely, microbial translocation has been indirectly impli-
cated in driving immune activation in chronically HIV-
infected humans and SIV-infected Rhesus macaques [19].
In keeping with this model, in HIV-negative individuals,
PBMCs stimulated in vitrowith LPS have been demonstrated
to increase the expression of CD38, and not HLA-DR [7].
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Consistent with these findings and with recent data
showing a dramatic decline in the percentages of DR+
subsets following PBMCs in vitro cultures [20], we hereby
show a reduction of HLA-DR+CD4+/CD8+ cells following
LPS in vitro stimulation in both healthy donors and HIV-
infected individuals. Interestingly enough however, when
evaluating HIV-patients according to the degree of immune
recovery on HAART, while HLA-DR expression was reduced
in patients with good CD4+ recovery, subjects with lower
CD4+ reconstitution, (i.e., LR and IR) maintained stable
HLA-DR-expressing T-cells. The net outcome of such diverse
eﬀect of LPS stimulation according to the extent of CD4+
recovery, is that subjects with poor immunological recovery
display significantly higher HLA-DR+ T-cell proportions. Of
note, LPS accounted for a higher proportion of proliferating
Ki67+ T-cells in the CD4+ subset alone, thus suggesting
that the combined eﬀect of microbial stimulation on T-cell
proliferation and activation seems to be restricted to the
CD4+ cell compartment.
By demonstrating highest LPS-dependant HLA-DR+ T-
cells exclusively in patients with lowest CD4+ recovery, our
findings add up to the consolidated bulk of evidence on
the inverse correlation between HLA-DR expression and
CD4+ lymphopenia [10, 17]. Thus, HLA-DR might be a
faithful marker of T-cell activation secondary to microbial
translocation in the setting of severe immune impairment.
A diﬀerent trend was shown in CD38-expressing T-cells
upon LPS stimulation.
The time-course analysis of the eﬀect of LPS stimulation
on CD38 expression showed an overall rise in CD38-
expressing T-cells that was, however, delayed in HIV-infected
patients compared to healthy controls (i.e., 48 versus 24
hours). Most interestingly, when investigating HIV-positive
subjects with diﬀerent immune recovery separately, only
patients with ineﬃcient CD4+ reconstitution (i.e., LR and
IR) displayed an expansion of the CD38+ T-cell pool,
whereas individuals with good immunological response
(HR) maintained a stable expression of CD38 on T-cells
overtime. Of note, although CD38 appeared selectively
induced on CD4+/CD8+ cells upon longer stimulation,
only CD38+CD8+ cells displayed a linear relationship
with immune impairment on HAART, with LR/IR patients
showing higher LPS-stimulated CD38+CD8+. Conversely,
no diﬀerences in CD38+CD4+ were shown according to the
degree of immune reconstitution.
These findings are consistent with in vivo data showing
that CD38+CD8+ T-cells are an independent predictor of
disease progression [8–11, 17]; although CD38 has been
described to have a similar prognostic value when expressed
on T CD4+ cells, this seems less consistent [8, 11, 12].
By showing higher LPS-induced expansion of
CD38+CD8+ cells, our findings suggest a diverse regulation
of CD38 in CD4+ and CD8+ T-cell compartments and
allow to speculate that the sole expression of CD38+ on
CD4+ T-cells may not be suﬃcient to portray the state of
immune activation in HIV disease. Indeed, CD38 has been
shown to be constitutively expressed on phenotypically
naı¨ve T-cells [13, 15, 21], thus oﬀsetting its role as an
activation marker in the CD4 pool. Indeed, in patients with
impaired immunological recovery in course of HAART,
Massanella et al. recently reported lower proportion
of CD38+CD45RA+CD4+ and higher percentage of
CD38+CD45RA-CD4+ cells, probably reflecting a reduced
naive compartment and a higher level of activation in
CD45RA- cells [21]. This finding is in keeping with data
from Benito et al. [12] who showed that CD38 expression
on CD4+ cells correlated with disease progression when
associated with the expression of phenotypic markers of
mermory/activated (CD45R0 or HLA-DR).
In our study, the co-induction of HLA-DR and CD38
on CD4+ and CD8+ T-cells followed similar kinetics upon
longer (48 hours) stimulation with LPS, with increased
levels of both molecules in subjects with severe immune
impairment on HAART. This finding, together with the
diﬀerential expression of single cell surface molecules, once
again suggests that CD38 on CD4+ cells may not faithfully
mirror activation in HIV disease.
The present study has several limitations. Our finding
of an in vitro eﬀect of LPS stimulation in reducing the
expression of activation markers cannot exclude the possi-
bility of increased cellular death following LPS challenge, as
previously shown in HIV-negative patients [7].
Our research was not designed to define the mechanisms
underlying variable LPS eﬀects and is therefore descriptive
in nature. Functional data on stimulated PBMCs, such as
the production of type I interferons and other cytokines,
would help give a qualitative answer to what activated cells
produce upon microbial challenge. In addition, data on
APC (macrophages, dendritic cells) activation and signalling
following TLR recognition and on the cooperation between
APCs and T-cells would shed light on the precise mecha-
nisms underlying T-lymphocyte activation upon microbial
stimulation.
As a further limitation, we chose to investigate the eﬀect
of LPS alone on T-cell activation. However, given that the
composition of translocating microflora may influence the
immunological response in course of treatment [22], it
would be interesting to study the eﬀect of other stimuli
(e.g., PHA, anti-CD3, PMA) as well as other TLR ligands,
representing microbial components from Gram-positive
bacteria (e.g., Pam3CysK4, TLR1/2 agonist; FSL-1, TLR6/2
agonist) or viral agents (e.g., ssRNA40, TLR8 agonist; CpG
oligonucleotide, TLR9 agonist) on T-cell activation and
response to HAART.
Our results thus advocate further functional studies to
gain deeper insight into the regulation of T-cell activation
by TLR agonists in course of HIV disease and response
to therapy. These data might provide the scientific back-
ground to investigate/explore alternative/adjuvant therapeu-
tical approaches in HIV infection aimed at manipulating the
negative eﬀects of LPS in inducing immune activation [23].
Acknowledgments
The authors are very thankful to all the patients participating
to the study and to all the staﬀ at the Clinic of Infectious
Diseases and Tropical Medicine, “San Paolo” Hospital,
Clinical and Developmental Immunology 9
University of Milan, Italy. This work was presented in part at
the 6thInternational AIDS Society (IAS) Conference, Rome,
Italy, 17–20 June, 2011.
References
[1] D. C. Douek, “Disrupting T-cell homeostasis: how HIV-1
infection causes disease,” AIDS Reviews, vol. 5, no. 3, pp. 172–
177, 2003.
[2] D. C. Douek, M. Roederer, and R. A. Koup, “Emerging
concepts in the immunopathogenesis of AIDS,”Annual Review
of Medicine, vol. 60, pp. 471–484, 2009.
[3] J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial
translocation is a cause of systemic immune activation in
chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp.
1365–1371, 2006.
[4] G. Marchetti, G. M. Bellistri, E. Borghi et al., “Microbial
translocation is associated with sustained failure in CD4+
T-cell reconstitution in HIV-infected patients on long-term
highly active antiretroviral therapy,” AIDS, vol. 22, no. 15, pp.
2035–2044, 2008.
[5] G. Marchetti, A. Gori, A. Casabianca et al., “Comparative
analysis of T-cell turnover and homeostatic parameters in
HIV-infected patients with discordant immune-virological
responses to HAART,” AIDS, vol. 20, no. 13, pp. 1727–1736,
2006.
[6] W. Jiang, M. M. Lederman, P. Hunt et al., “Plasma levels of
bacterial DNA correlate with immune activation and the mag-
nitude of immune restoration in persons with antiretroviral-
treated HIV infection,” Journal of Infectious Diseases, vol. 199,
no. 8, pp. 1177–1185, 2009.
[7] N. Funderburg, A. A. Luciano, W. Jiang, B. Rodriguez, S.
F. Sieg, and M. M. Lederman, “Toll-like receptor ligands
induce human T cell activation and death, a model for HIV
pathogenesis,” PLoS One, vol. 3, no. 4, Article ID e1915, 2008.
[8] J. V. Giorgi, L. E. Hultin, J. A. McKeating et al., “Shorter
survival in advanced human immunodeficiency virus type
1 infection is more closely associated with T lymphocyte
activation than with plasma virus burden or virus chemokine
coreceptor usage,” Journal of Infectious Diseases, vol. 179, no.
4, pp. 859–870, 1999.
[9] J. V. Giorgi, R. H. Lyles, J. L. Matud et al., “Predictive value
of immunologic and virologic markers after long or short
duration of HIV-1 infection,” Journal of Acquired Immune
Deficiency Syndromes, vol. 29, no. 4, pp. 346–355, 2002.
[10] Z. Liu, W. G. Cumberland, L. E. Hultin, H. E. Prince, R.
Detels, and J. V. Giorgi, “Elevated CD38 antigen expression
on CD8+ T cells Is a stronger marker for the risk of chronic
HIV disease progression to AIDS and death in the multicenter
AIDS Cohort study than CD4+ cell count, soluble immune
activation markers, or combinations of HLA-DR and CD38
expression,” Journal of Acquired Immune Deficiency Syndromes
and Human Retrovirology, vol. 16, no. 2, pp. 83–92, 1997.
[11] S. G. Deeks, C.M. R. Kitchen, L. Liu et al., “Immune activation
set point during early HIV infection predicts subsequent
CD4+ T-cell changes independent of viral load,” Blood, vol.
104, no. 4, pp. 942–947, 2004.
[12] J. M. Benito, J. M. Zabay, J. Gil et al., “Quantitative alterations
of the functionally distinct subsets of CD4 and CD8 T
lymphocytes in asymptomatic HIV infection: changes in the
expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR,
and CD25 antigens,” Journal of Acquired Immune Deficiency
Syndromes and Human Retrovirology, vol. 14, no. 2, pp. 128–
135, 1997.
[13] A. Savarino, F. Bottarel, F. Malavasi, and U. Dianzani, “Role
of CD38 in HIV-1 infection: an epiphenomenon of T-cell
activation or an active player in virus/host interactions?”
AIDS, vol. 14, no. 9, pp. 1079–1089, 2000.
[14] K. Mehta, U. Shahid, and F. Malavasi, “Human CD38, a cell-
surface protein with multiple functions,” FASEB Journal, vol.
10, no. 12, pp. 1408–1417, 1996.
[15] K. Scalzo-Inguanti andM. Plebanski, “CD38 identifies a hypo-
proliferative IL-13-secreting CD4+ T-cell subset that does not
fit into existing naive and memory phenotype paradigms,”
European Journal of Immunology, vol. 41, no. 5, pp. 1298–1308,
2011.
[16] L. Gazzola, C. Tincati, G. M. Bellistrı`, A. D. Monforte, and G.
Marchetti, “The absence of CD4+ T cell count recovery despite
receipt of virologically suppressive highly active antiretroviral
therapy: clinical risk, immunological gaps, and therapeutic
options,” Clinical Infectious Diseases, vol. 48, no. 3, pp. 328–
337, 2009.
[17] P. W. Hunt, J. N. Martin, E. Sinclair et al., “T cell activation
is associated with lower CD4+ T cell gains in human
immunodeficiency vires-infected patients with sustained viral
suppression during antiretroviral therapy,” Journal of Infec-
tious Diseases, vol. 187, no. 10, pp. 1534–1543, 2003.
[18] J. D. Estes, L. D. Harris, N. R. Klatt et al., “Damaged
intestinal epithelial integrity linked to microbial translocation
in pathogenic simian immunodeficiency virus infections,”
PLoS Pathogens, vol. 6, no. 8, Article ID e1001052, pp. 49–50,
2010.
[19] M. Paiardini, I. Pandrea, C. Apetrei, and G. Silvestri, “Lessons
learned from the natural hosts of HIV-related viruses,” Annual
Review of Medicine, vol. 60, pp. 485–495, 2009.
[20] A. L. Meditz, M. K. Haas, J. M. Folkvord et al., “HLA-DR+
CD38+ CD4+ T lymphocytes have elevated CCR5 expression
and produce the majority of R5-tropic HIV-1 RNA in vivo,”
Journal of Virology, vol. 85, no. 19, pp. 10189–10200, 2011.
[21] M. Massanella, E. Negredo, N. Perez-Alvarez et al., “CD4 T-
cell hyperactivation and susceptibility to cell death determine
poor CD4 T-cell recovery during suppressive HAART,” AIDS,
vol. 24, no. 7, pp. 959–968, 2010.
[22] E. Merlini, F. Bai, G. M. Bellistrı`, C. Tincati, A. d’Arminio
Monforte, and G. Marchetti, “Evidence for polymicrobic flora
translocating in peripheral blood of HIV-infected patients
with poor immune response to antiretroviral therapy,” PLoS
One, vol. 6, no. 4, Article ID e18580, 2011.
[23] S. Piconi, S. Parisotto, G. Rizzardini et al., “Hydroxychloro-
quine drastically reduces immune activation in HIV-infected,
antiretroviral therapy-treated immunologic nonresponders,”
Blood, vol. 118, no. 12, pp. 3263–3272, 2011.
